It remains to be clarified whether naïve CD4+ T cells might be of regulatory phenotype and nature in the CNS, and could therefore provide an opportunity for a novel therapeutic approach in MS or other autoimmune diseases. This evidence concerns the gene CD4 and myeloid sarcoma.